Two highly reactive heterodinuclear bis(mu-oxo) complexes were prepared by combining mononuclear peroxo species with reduced metal precursors at -80 degrees C and were identified by UV-vis, EPR/NMR, ...and resonance Raman spectroscopy, with corroboration in the case of the CuPd system from density functional calculations.
This report describes the synthesis of 4-substituted- and 1,4-disubstituted-4-hydroxypyrrolidin-2-ones by cyclization of intermediate γ-aminoesters prepared from alkylbenzylamines, α-bromoketones, ...and lithio ethyl acetate.
Annual low-radiation-dose computed tomography (LDCT) screening for lung cancer has been shown to reduce lung cancer mortality among high-risk individuals and is now recommended by multiple ...organizations. However, LDCT screening is complex, and implementation requires careful planning to ensure benefits outweigh harms. Little guidance has been provided for sites wishing to develop and implement lung cancer screening programs.
To promote successful implementation of comprehensive LDCT screening programs that are safe, effective, and sustainable.
The American Thoracic Society (ATS) and American College of Chest Physicians (ACCP) convened a committee with expertise in lung cancer screening, pulmonary nodule evaluation, and implementation science. The committee reviewed the evidence from systematic reviews, clinical practice guidelines, surveys, and the experience of early-adopting LDCT screening programs and summarized potential strategies to implement LDCT screening programs successfully.
We address steps that sites should consider during the main three phases of developing an LDCT screening program: planning, implementation, and maintenance. We present multiple strategies to implement the nine core elements of comprehensive lung cancer screening programs enumerated in a recent ACCP/ATS statement, which will allow sites to select the strategy that best fits with their local context and workflow patterns. Although we do not comment on cost-effectiveness of LDCT screening, we outline the necessary costs associated with starting and sustaining a high-quality LDCT screening program.
Following the strategies delineated in this policy statement may help sites to develop comprehensive LDCT screening programs that are safe and effective.
The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium is applying the latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome ...Atlas (TCGA) program, a joint initiative of the NCI and the National Human Genome Research Institute. By providing a fully integrated accounting of DNA, RNA, and protein abnormalities in individual tumors, these datasets will illuminate the complex relationship between genomic abnormalities and cancer phenotypes, thus producing biologic insights as well as a wave of novel candidate biomarkers and therapeutic targets amenable to verification using targeted mass spectrometry methods.
Proteomics holds great promise in personalized medicine for cancer in the post‐genomic era. In the past decade, clinical proteomics has significantly evolved in terms of technology development, ...optimization and standardization, as well as in advanced bioinformatics data integration and analysis. Great strides have been made for characterizing a large number of proteins qualitatively and quantitatively in a proteome, including the use of sample fractionation, protein microarrays and MS. It is believed that differential proteomic analysis of high‐quality clinical biospecimen (tissue and biofluids) can potentially reveal protein/peptide biomarkers responsible for cancer by means of their altered levels of expression and/or PTMs. Multiple reaction monitoring, a multiplexed platform using stable isotope dilution‐MS with sensitivity and reproducibility approaching that of traditional ELISAs commonly used in the clinical setting, has emerged as a potentially promising technique for next‐generation high‐throughput protein biomarker measurements for diagnostics and therapeutics.
Die Aufspaltung der Grenzorbitale und damit der Diradikalcharakter von 1,3‐Diphospha‐2,4‐diboretanen lassen sich durch Variieren der Phosphor‐Substituenten R weitestgehend kontrollieren (siehe ...Schema; z. B. R=SiMe3, R′=tBu).
PDF
